EPIX Pharmaceuticals : Phase 2a Data at American Thoracic Society Meeting

May 15, 2008 - EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced that Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX, is scheduled to present an oral presentation entitled "Selective Serotonin-2B Receptor Antagonist PRX-08066 Improves Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease" at the International Conference of the American Thoracic Society in Toronto on Wednesday, May 21, 2008 at 2:50 p.m. ET.

EPIX previously announced the results of a Phase 2a clinical trial of PRX-08066 in patients with pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD)... EPIX Pharmaceuticals' Press Release -

EPIX Pharmaceuticals, Collaboration with Cystic Fibrosis Foundation Therapeutics

Jan. 23, 2008 - EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced that it has received a $1.25 million milestone payment from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation. This milestone marks EPIX and CFFT's successful completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel protein. A mutation in the CFTR gene that codes for this channel is one of the key factors that ultimately lead to the symptoms, complications and premature mortality in people with cystic fibrosis... EPIX' Press Release-